HK1181816A1 - 用於胃癌檢測的標記物 - Google Patents

用於胃癌檢測的標記物

Info

Publication number
HK1181816A1
HK1181816A1 HK13108890.9A HK13108890A HK1181816A1 HK 1181816 A1 HK1181816 A1 HK 1181816A1 HK 13108890 A HK13108890 A HK 13108890A HK 1181816 A1 HK1181816 A1 HK 1181816A1
Authority
HK
Hong Kong
Prior art keywords
detection
gtm
gastric
tumors
markers
Prior art date
Application number
HK13108890.9A
Other languages
English (en)
Inventor
Parry John Guilford
Andrew John Holyoake
Original Assignee
Pacific Edge Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacific Edge Biotechnology Ltd filed Critical Pacific Edge Biotechnology Ltd
Publication of HK1181816A1 publication Critical patent/HK1181816A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Sustainable Development (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HK13108890.9A 2003-07-17 2013-07-30 用於胃癌檢測的標記物 HK1181816A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48790603P 2003-07-17 2003-07-17

Publications (1)

Publication Number Publication Date
HK1181816A1 true HK1181816A1 (zh) 2013-11-15

Family

ID=34102728

Family Applications (3)

Application Number Title Priority Date Filing Date
HK07104969.2A HK1098513A1 (en) 2003-07-17 2007-05-10 Markers for detection of gastric cancer
HK13108890.9A HK1181816A1 (zh) 2003-07-17 2013-07-30 用於胃癌檢測的標記物
HK16109525.7A HK1221489A1 (zh) 2003-07-17 2016-08-10 用於胃癌檢測的標記物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK07104969.2A HK1098513A1 (en) 2003-07-17 2007-05-10 Markers for detection of gastric cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16109525.7A HK1221489A1 (zh) 2003-07-17 2016-08-10 用於胃癌檢測的標記物

Country Status (12)

Country Link
US (2) US10179935B2 (zh)
EP (3) EP2325338B1 (zh)
JP (3) JP4936887B2 (zh)
CN (3) CN105316405A (zh)
AT (1) ATE511550T1 (zh)
AU (1) AU2004260083B2 (zh)
BR (1) BRPI0412725B8 (zh)
CA (2) CA2532722C (zh)
ES (3) ES2481672T3 (zh)
HK (3) HK1098513A1 (zh)
NZ (3) NZ588323A (zh)
WO (1) WO2005010213A2 (zh)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374886B2 (en) 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
EP1619206A3 (en) 1999-04-09 2006-02-15 Rigshospitalet Tissue inhibitor of matrix metallproteinases type-1 (TIMP-1) as a cancer marker
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US10533998B2 (en) 2008-07-18 2020-01-14 Bio-Rad Laboratories, Inc. Enzyme quantification
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
AU2005297303B2 (en) * 2004-10-19 2011-11-10 Lsip, Llc Novel diagnostic kit for malignant melanoma
ITVI20050059A1 (it) * 2005-03-04 2006-09-05 Consorzio Per Gli Studi Universitari In Verona Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US20070021365A1 (en) * 2005-06-21 2007-01-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
EP1984738A2 (en) 2006-01-11 2008-10-29 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
EP2530167A1 (en) 2006-05-11 2012-12-05 Raindance Technologies, Inc. Microfluidic Devices
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
JP2008118915A (ja) * 2006-11-10 2008-05-29 Kazuto Nishio 胃癌高発現遺伝子特定による胃癌診断および創薬への利用
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
JP2008278798A (ja) * 2007-05-10 2008-11-20 Tokyo Medical & Dental Univ 膀胱癌の検出方法
CN101835490A (zh) 2007-08-02 2010-09-15 阿雷斯托生物科学股份有限公司 Lox和loxl2抑制剂及其应用
EP3106873B1 (en) * 2007-10-25 2019-07-17 Toray Industries, Inc. Method for detection of cancer
KR101007569B1 (ko) 2008-04-21 2011-01-14 한국생명공학연구원 위암 진단 마커로서의 씨에스티원
WO2009131365A2 (ko) * 2008-04-21 2009-10-29 한국생명공학연구원 위암 진단 마커로서의 ｃst1, ｄcc1, ifitm1 또는 ｍelk
WO2009139915A2 (en) * 2008-05-15 2009-11-19 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
EP2315629B1 (en) 2008-07-18 2021-12-15 Bio-Rad Laboratories, Inc. Droplet libraries
US9107935B2 (en) * 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
AU2010248227B2 (en) * 2009-05-15 2016-02-25 Pacific Edge Limited Markers for detection of gastric cancer
CA2960887C (en) 2009-05-28 2018-09-04 Abraxis Bioscience, Llc Use of 2 anti-sparc antibodies to predict response to chemotherapy
US20110044907A1 (en) * 2009-08-21 2011-02-24 Derek Marshall In vivo screening assays
SG2014004816A (en) * 2009-08-21 2014-03-28 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
RU2012110587A (ru) * 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Терапевтические способы и композиции
JP2013502228A (ja) * 2009-08-21 2013-01-24 ギリアド バイオロジクス，インク． ｉｎｖｉｔｒｏスクリーニングアッセイ
CA2771786A1 (en) * 2009-08-21 2011-02-24 Gilead Biologics, Inc. In vivo screening assays
JP2013505268A (ja) * 2009-09-18 2013-02-14 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー 癌の治療におけるｓｐａｒｃ微小環境シグネチャの使用
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
KR101692063B1 (ko) * 2009-12-09 2017-01-03 닛토덴코 가부시키가이샤 hsp47 발현의 조절
EP2513649B1 (en) 2009-12-20 2016-04-20 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
RU2549684C2 (ru) 2010-02-04 2015-04-27 Джилид Байолоджикс, Инк. Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
WO2011097539A1 (en) * 2010-02-05 2011-08-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8709732B2 (en) * 2010-02-11 2014-04-29 The Hong Kong Polytechnic University Biomarkers of gastric cancer and use thereof
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
EP2534267B1 (en) 2010-02-12 2018-04-11 Raindance Technologies, Inc. Digital analyte analysis
EP2575863A4 (en) 2010-06-03 2014-04-09 Abraxis Bioscience Llc USE OF SPARC MICROENVIRONMENT SIGNATURE IN THE TREATMENT OF CANCER
CN102296104A (zh) * 2010-06-24 2011-12-28 中国科学院上海生命科学研究院 癌症发生或转移的诊断试剂
CN102346188B (zh) * 2010-08-03 2014-07-23 中国人民解放军军事医学科学院生物工程研究所 Thbs-1的新用途
EP3447155A1 (en) 2010-09-30 2019-02-27 Raindance Technologies, Inc. Sandwich assays in droplets
EP2463657A1 (en) * 2010-12-13 2012-06-13 Université de Liège Biomarkers, uses of biomarkers and a method of identifying biomarkers
DK2666014T3 (en) * 2011-01-21 2017-01-09 Basilea Pharmaceutica Ag USE OF GLU-tubulin as a biomarker of PHARMACEUTICAL RESPONSE TO FURAZANOBENZIMIDAZOLER
EP3859011A1 (en) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Methods for forming mixed droplets
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
CA2827200A1 (en) 2011-02-24 2012-08-30 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a feline
CN105886649A (zh) * 2011-02-24 2016-08-24 希尔氏宠物营养品公司 用于在猫科动物中诊断和治疗肾功能障碍的组合物和方法
WO2013101276A2 (en) * 2011-04-01 2013-07-04 Mount Sinai School Of Medicine Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway
ITAN20110057A1 (it) 2011-05-02 2012-11-03 Mario Castellucci Identificazione di un nuovo fattore molecolare per la diagnosi precoce del carcinoma uroteliale della vescica.
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
KR101311718B1 (ko) 2011-07-05 2013-09-25 한국과학기술연구원 대장암 진단용 단백질 마커 ｒｐｅ-스폰딘 및 이에 대한 항체를 포함하는 대장암 진단 키트
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
US10935548B2 (en) * 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
JP6192122B2 (ja) * 2012-01-09 2017-09-06 スージョウ マイクロダイアグ バイオメディスン カンパニー リミテッド 結腸直腸癌診断および予測のためのバイオマーカー
CN104136630B (zh) * 2012-01-09 2017-04-05 苏州工业园区为真生物医药科技有限公司 诊断和预示乳腺癌的标志物
WO2013104102A1 (zh) * 2012-01-09 2013-07-18 苏州工业园区为真生物医药科技有限公司 乳腺癌诊断和预示的标志物
EP3495817A1 (en) 2012-02-10 2019-06-12 Raindance Technologies, Inc. Molecular diagnostic screening assay
WO2013147330A1 (ko) * 2012-03-26 2013-10-03 연세대학교 산학협력단 국소 진행형 위암에 대한 예후 예측 시스템
EP3524693A1 (en) 2012-04-30 2019-08-14 Raindance Technologies, Inc. Digital analyte analysis
EP2854910B1 (en) 2012-06-01 2020-04-15 Icahn School of Medicine at Mount Sinai Ceramide levels in the treatment and prevention of infections
CN105074466B (zh) 2013-01-17 2018-01-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CA2898446A1 (en) 2013-01-20 2014-07-24 Dyax Corp. Evaluation, assays and treatment of pkal-mediated disorders
JP6832158B2 (ja) 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
CN103926409B (zh) * 2013-05-07 2015-11-25 上海良润生物医药科技有限公司 Cystatin S和AFP在制备诊断和预示肝癌标志物中的应用
CN103913574B (zh) * 2013-05-07 2016-04-06 上海良润生物医药科技有限公司 半胱氨酸蛋白酶抑制剂s与癌胚抗原的联合应用
CN103913575B (zh) * 2013-05-07 2016-02-10 上海良润生物医药科技有限公司 半胱氨酸蛋白酶抑制剂s与糖类抗原19-9的联合应用
CN103901196B (zh) * 2013-05-07 2016-04-27 上海良润生物医药科技有限公司 Cystatin S和CYFRA21-1在制备诊断和预示食管癌标志物中的应用
CN103913576B (zh) * 2013-05-07 2016-03-16 上海良润生物医药科技有限公司 Cystatin SN 和CA15-3在制备诊断和预示乳腺癌标志物中的应用
IL300761A (en) 2013-08-05 2023-04-01 Immatics Biotechnologies Gmbh Innovative immunotherapy against several tumors, such as lung cancer, including NSCLC
US20160220711A1 (en) * 2013-09-13 2016-08-04 The University Of North Carolina At Chapel Hill Methods and compositions for tumor vasculature imaging and targeted therapy
JP6546178B2 (ja) * 2013-09-13 2019-07-17 ジェネンテック， インコーポレイテッド 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
CN110007084B (zh) 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
EP3090063B1 (en) 2013-12-31 2019-11-06 Bio-Rad Laboratories, Inc. Method for detection of latent retrovirus
WO2015172201A1 (en) * 2014-05-16 2015-11-19 Peter Maccallum Cancer Institute Biomarker of gastric cancer
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
CN105572354B (zh) * 2014-10-17 2018-02-02 广州瑞博奥生物科技有限公司 一种检测早期胃癌的抗体芯片试剂盒
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
MA43958A (fr) * 2016-02-01 2018-12-12 Bayer Pharma AG Biomarqueurs copanlisib
CN107153117B (zh) * 2016-03-04 2019-02-19 中国人民解放军军事医学科学院生物工程研究所 一种用于判断靶向单克隆抗体***疗效的预测分子
CN105779635B (zh) * 2016-05-18 2019-10-22 黄文林 一种基于olfm1基因用于结直肠癌预后判断的试剂盒
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
CN106290899A (zh) * 2016-07-29 2017-01-04 上海良润生物医药科技有限公司 用于定量检测半胱氨酸蛋白酶抑制剂s的试剂盒
CN106501517B (zh) * 2016-12-27 2018-05-08 北京蛋白质组研究中心 检测血清中sparc蛋白的物质在制备筛查肝细胞癌试剂盒中的应用
CN107037210A (zh) * 2017-04-05 2017-08-11 北京蛋白质组研究中心 Thbs2蛋白检测物在制备肝细胞癌诊断试剂盒中的应用
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
US11851475B2 (en) 2018-01-03 2023-12-26 Xi'an Jiaotong-Liverpool University Membrane-type metalloprotease inhibitory protein and pharmaceutical and pharmaceutical composition containing same, and respective uses thereof
CN108314727B (zh) * 2018-01-03 2021-08-06 西交利物浦大学 膜型金属蛋白酶抑制蛋白及其用途
CN110295230A (zh) * 2018-03-23 2019-10-01 中山大学 分子标志物inhba和spp1及其应用
SI3794148T1 (sl) * 2018-05-17 2022-11-30 Twobull Meditherapy P. C. Postopki za diagnostiko anevrizme ali raka
CN108977511A (zh) * 2018-07-03 2018-12-11 张罗 检测鼻腔脱落细胞中cst1基因表达量的方法及应用
CN109320597B (zh) * 2018-10-26 2021-10-26 中国农业科学院特产研究所 狐亚科激活素a蛋白及其制备与应用
KR20210153097A (ko) 2019-04-16 2021-12-16 다케다 파머수티컬 컴패니 리미티드 기능성 c1 에스테라제 저해제(fc1-inh)의 정량 방법
CN110699358B (zh) * 2019-11-20 2023-05-02 天津师范大学 一种提高中华绒螯蟹抗病性的双链rna及其应用
CN114836539B (zh) * 2022-05-06 2022-12-06 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种用于胃癌转移预测和预后判断的circRNA标志物及应用
CN114720687A (zh) * 2022-06-01 2022-07-08 浙江省肿瘤医院 Sfrp4作为胃癌预后标志物的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470970A (en) * 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
FI971124A0 (fi) 1997-03-18 1997-03-18 Locus Genex Oy Metod foer diagnostisering av magcancer
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
AU6181200A (en) * 1999-07-29 2001-02-19 Helix Research Institute Stomach cancer-associated gene
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
CA2411601A1 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
JP2002085093A (ja) * 2000-09-08 2002-03-26 Kuo Kwang Biotech Corp 扁平上皮細胞癌患者の生存予測
JP2002209600A (ja) * 2000-12-25 2002-07-30 Academia Sinica 胃ガンを診断および処置する方法
JPWO2002064769A1 (ja) * 2001-02-15 2004-06-17 塩野義製薬株式会社 新規疾患マーカー
JPWO2002083899A1 (ja) * 2001-04-10 2004-08-05 タカラバイオ株式会社 癌関連遺伝子
AU2002309583A1 (en) * 2001-04-18 2002-11-05 Protein Desing Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
JP2003004739A (ja) * 2001-06-26 2003-01-08 Takara Bio Inc 遺伝子発現プロファイル解析方法及び装置
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20030232350A1 (en) * 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003057916A2 (en) * 2002-01-09 2003-07-17 Riken Cancer profiles
AU2003298786A1 (en) * 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20040258696A1 (en) * 2003-02-05 2004-12-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
ES2535261T3 (es) 2015-05-07
US20160369355A1 (en) 2016-12-22
ES2481672T3 (es) 2014-07-31
CN1867679B (zh) 2012-10-03
CN105316405A (zh) 2016-02-10
JP2011250795A (ja) 2011-12-15
EP2325338B1 (en) 2015-01-21
WO2005010213A2 (en) 2005-02-03
BRPI0412725A (pt) 2006-09-26
CA2532722C (en) 2016-10-04
JP2007531500A (ja) 2007-11-08
HK1221489A1 (zh) 2017-06-02
NZ544977A (en) 2009-07-31
JP5616857B2 (ja) 2014-10-29
HK1098513A1 (en) 2007-07-20
CN1867679A (zh) 2006-11-22
EP2305833A2 (en) 2011-04-06
EP1649064A2 (en) 2006-04-26
CN102899398A (zh) 2013-01-30
JP5959579B2 (ja) 2016-08-02
EP1649064B1 (en) 2011-06-01
BRPI0412725B8 (pt) 2021-07-27
JP2014236737A (ja) 2014-12-18
CA2895272A1 (en) 2005-02-03
ATE511550T1 (de) 2011-06-15
US10179935B2 (en) 2019-01-15
AU2004260083B2 (en) 2011-04-07
BRPI0412725B1 (pt) 2017-06-20
AU2004260083A1 (en) 2005-02-03
EP2325338A2 (en) 2011-05-25
ES2369667T3 (es) 2011-12-02
EP2305833A3 (en) 2012-02-01
NZ575886A (en) 2010-11-26
US20070184439A1 (en) 2007-08-09
JP4936887B2 (ja) 2012-05-23
WO2005010213A3 (en) 2005-09-15
NZ588323A (en) 2012-04-27
CN102899398B (zh) 2015-09-30
US10689707B2 (en) 2020-06-23
CA2532722A1 (en) 2005-02-03
EP2305833B1 (en) 2014-04-16
EP2325338A3 (en) 2011-10-12

Similar Documents

Publication Publication Date Title
HK1221489A1 (zh) 用於胃癌檢測的標記物
Oremek et al. Physical activity releases prostate-specific antigen (PSA) from the prostate gland into blood and increases serum PSA concentrations
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
WO2004032621A3 (en) Techniques for identifying molecular structures and treating cell types lining a body lumen using fluorescence
WO2002083070A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001096388A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
EP1466179A4 (en) METHOD FOR DIAGNOSIS OF CANCER DISORDERS BY MEASURING THE CHANGES TO GLOBALIZATION OF PROTEINS RELATED TO TUMOR FORMATION AND METASTASE, AND TO THE USE THEREOF FOR THE DIAGNOSIS OF CANCER DISORDERS
WO2005095638A3 (en) A kit for measuring the thrombin generation in a sample of a patient’s blood or plasma
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
CA2366682A1 (en) Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
Zeyad et al. The importance of alpha-1 antitrypsin (α1-AT) and neopterin serum levels in the evaluation of nonsmall cell lung and prostate cancer patients
HK1115166A1 (en) Methods for detecting progression of low grade cervical dysplasia
AU4985201A (en) Human gene critical to fertility
Warwas et al. Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
TW200604528A (en) Markers for detection of gastric cancer
WO2003099107A3 (en) Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient
WO2001062785A3 (en) Protein and gene and their use for diagnosis and treatment of schizophrenia
WO2001070976A3 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
US20070207509A1 (en) Zinc-based screening test and kit for early diagnosis of prostate cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200721